We are live on ! Find out more
MYOK

MyoKardia, Inc. Common Stock
MYOK

Delisted

MYOK was delisted on the 16th of November, 2020.

Back to rankings

75 hedge funds and large institutions have $207M invested in MyoKardia, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 37 increasing their positions, 19 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 19

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

6% more capital invested

Capital invested by funds: $196M → $207M (+$11.3M)

3% more funds holding

Funds holding: 73 → 75 (+2)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
75
Holders Change
+2
Holders Change %
+2.74%
% of All Funds
1.86%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
37
Reduced
19
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$3.19M
2
BlackRock
BlackRock
New York
+$2.71M
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.08M
4
OAM
Oxford Asset Management
United Kingdom
+$1.77M
5
PHS
PFM Health Sciences
California
+$1.73M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$7.32M
2
DM
Deerfield Management
New York
-$1.91M
3
CAM
Cormorant Asset Management
Massachusetts
-$1.71M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.55M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$1.24M

MYOK Hedge Fund Activity: Q2 2017 in Review

75 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in MyoKardia, Inc. Common Stock (MYOK) for Q2 2017, worth a combined $207M — up 5.8% from $196M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new MYOK positions and 10 closed out — a net gain of 2 holders — while 37 added to existing stakes and 19 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $3.19M. The largest seller was Fidelity Investments, cutting an estimated $7.32M.

  • 75 institutional investors held MyoKardia, Inc. Common Stock (MYOK) as of Q2 2017, up from 73 in Q1 2017.
  • Funds reported $207M of MyoKardia, Inc. Common Stock stock for Q2 2017, up 5.8% quarter-over-quarter.
  • 12 funds opened new MyoKardia, Inc. Common Stock positions in Q2 2017 and 10 closed out, a net change of +2 holders.
  • The largest MyoKardia, Inc. Common Stock buyer in Q2 2017 was JP Morgan Chase, an estimated $3.19M added.
  • The largest MyoKardia, Inc. Common Stock seller in Q2 2017 was Fidelity Investments, an estimated $7.32M sold.

Based on aggregated 13F filings for Q2 2017.